|
Video: What is a Stock Split?
|
|
NexImmune is a clinical-stage biotechnology company developing an approach to immunotherapy designed to employ the body's own T cells to generate a specific immune response that mimics natural biology. Co. has two product candidates: NEXI-001 in acute myeloid leukemia, and NEXI-002 in multiple myeloma. Co.'s product candidates are adoptive T cell therapies (ACTs) that contain populations of naturally occurring CD8+ T cells that recognize a defined set of disease-relevant antigen targets. In addition to its programs using the Artificial Immune Modulation (AIM) ACT adoptive cell therapy modality, Co. is also developing an off-the-shelf injectable modality, which it refers to as AIM INJ. According to our NEXI split history records, NexImmune has had 1 split. | |
|
NexImmune (NEXI) has 1 split in our NEXI split history database. The split for NEXI took place on October 19, 2023. This was a 1 for 25 reverse split, meaning for each 25 shares of NEXI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as NexImmune conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the NEXI split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into NexImmune shares, starting with a $10,000 purchase of NEXI, presented on a split-history-adjusted basis factoring in the complete NEXI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/16/2021 |
|
End date: |
04/16/2024 |
|
Start price/share: |
$582.75 |
|
End price/share: |
$3.47 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.40% |
|
Average Annual Total Return: |
-80.22% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$59.55 |
|
Years: |
3.16 |
|
|
|
Date |
Ratio |
10/19/2023 | 1 for 25 |
|
|